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Abstract
Background: Inflammation is a key feature of HIV infection and is correlated with long-term negative cardiovascular
outcomes. Therapy-induced increases in CD4+ cell counts can control inflammation, as shown by decreases of coagulation
and inflammation markers during efficacious therapy. Maraviroc, a CCR5-antagonist, has resulted in larger increases in CD4+
counts both in naı¨ve and experienced subjects compared to traditional antiretroviral therapy.
Objectives and Methods: To examine if a member of the protein C anticoagulant and anti-inflammatory pathway, and
marker of coagulation and inflammation, the soluble endothelial protein C receptor, is modified by infection and therapy-
related variables in patients treated with Maraviroc. Endothelial protein C receptor, together with other established markers
of inflammation and coagulation (CRP, IL-6, D-dimer and soluble thrombomodulin) was studied in 43 patients on traditional
antiretroviral therapy and in 45 on Maraviroc during 48 weeks of follow-up.
Results: Soluble endothelial protein C receptor was the only marker that could discriminate at least partially between
patients with a good response to Maraviroc and patients who did not respond with an adequate increase in CD4+ cell
counts (more than 500 cells/mL by week 48).
Conclusions: Elevated levels of soluble endothelial protein C receptor, a sensitive marker of endothelial damage, indicated a
low level of inflammation and coagulation activation in Maraviroc treated patients not picked up by other widely used
markers. Persistent elevated levels of this marker at 48 weeks from beginning of treatment with Maraviroc were related to a
poor increase in CD4+ cells.
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Introduction
Persistent chronic inflammation is a key feature of HIV
infection and it has many consequences, including an increased
risk of cardiovascular events, compounded by other risk factors
peculiar to HIV patients, such as certain therapeutic agents and
lifestyle factors [1,2]. Similarly to non infected patients, chronic
inflammation as measured by biological markers, increases the
likelihood of ischemic heart disease, approximately twofold in
HIV+ patients. Infection by HIV was shown to induce oxidative
stress and nitric oxide depletion on the endothelium and to impair
endothelium dependent vasodilation [3,4]. Low CD4+ cell counts
were independently associated with an increased prevalence of
carotid lesions [5]. Elevated levels of the pro-inflammatory
cytokine interleukin-6, the fibrinolysis marker D-dimer and the
acute phase protein CRP were associated with increased
cardiovascular and all-cause-mortality in the SMART study, a
large treatment interruption trial [6]. Moreover, in another
treatment interruption trial, several inflammatory markers were
found to be suppressed during treatment, and to rise during
treatment interruption and the opposite was true for the anti-
inflammatory biomarkers interleukin-10 and adiponectin [7].
The understanding of the regulation of the inflammatory
response in stable HIV+ patients and of the effect of the different
therapeutic agents on inflammatory markers is key to preventing
cardiovascular disease and to identifying appropriate markers
potentially predictive of cardiovascular disease and/or of response
to the anti-inflammatory effect of therapy. Since inflammation and
coagulation work together, it is reasonable to suppose that novel
markers of regulatory coagulation pathways could be useful in this
setting.
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The protein C system is one of the main regulatory pathways
of blood clotting: activated protein C inhibits two cofactors of
the coagulation cascade (activated factors V and VIII) thereby
limiting thrombin formation [8]. Protein C is activated on the
endothelial surface by thrombin bound to the receptor
thrombomodulin and aided by the endothelial protein C
receptor (EPCR). Endothelial perturbation, especially by inflam-
mation, negatively affects protein C activation by down-
regulating the protein C pathway by several mechanisms [8].
Both thrombomodulin and EPCR are shed from the endothelial
membrane during inflammation and can be measured in blood
as soluble products [9,10].
Treatment with CCR5-antagonist Maraviroc (MVC) has
resulted in larger increases in CD4+ counts both in naı¨ve [11]
and experienced subjects [12]. Naı¨ve patients treated with MVC
had earlier decreases in markers of immune activation and
inflammation, correlated with increased CD4+ cells [13]. In this
study a small cohort of HIV patients treated with MVC was
studied and compared over time with patients treated with
traditional therapy to gain a preliminary insight into the usefulness
of a panel of markers of inflammation, hemostasis and endothelial
function including markers of the protein C pathway. We show
that soluble EPCR (sEPCR) is a potentially useful marker of
persistent inflammation and treatment failure in patients treated
with MVC and that it is more sensitive than other traditional
markers of inflammation and clotting.
Methods
Patients
Eighty-eight HIV-infected patients were enrolled in the study
after providing written informed consent approved by San
Raffaele ethics committee. There were 70 men and 18 women,
median age was 49 years (range). Forty-three were on
antiretroviral therapy (ART) while 45 were on ART and were
placed on MVC at the beginning of the study (defined as
baseline), according to screening genotype, previous resistance
tests and viral tropism determined by the phenotypic test
TrofileH. Median time from diagnosis at baseline was 16 years
(range 5–23).
Blood sampling as well as a medical visit were performed at
baseline and at 4, 12, 24, 36 and 48 weeks after starting therapy.
Blood for coagulation and inflammation markers was collected in
trisodium EDTA, centrifuged at 1400 g for 15 min and platelet
poor plasma was separated and stored at 280uC. Plasma samples
were rapidly melted in a 37uC water bath before testing. No
refrozen samples were used.
The following variables were measured at each time point:
blood glucose and insulin, lipid profile, and variables related to
viral infection (CD4+ absolute count and percentage, CD4+/CD8+
ratio, HIV-RNA). Coagulation and inflammation markers [high
sensitivity C-reactive protein (hsCRP), D-dimer (DD), interleukin-
6 (IL-6), soluble thrombomodulin (sTM) and sEPCR] were
measured up to week 24, except for sEPCR which was measured
also at weeks 36 and 48.
At baseline, 24 and 48 weeks liver metabolism and HIV-DNA
were evaluated as well.
Methods
Measurement of Biological Variables
Hs-CRP was measured by IMUCLONE CRP ELISA kit
(American Diagnostica Inc, Stamford, CT, USA). Each assay
contained a low level and a high level control. Inter-assay
coefficient of variation (CV) for the high level was 8% and for the
low level 16%. Normal reference range is: 0.2–10 mg/mL.
D-dimer was measured by IMUCLONE D-Dimer ELISA
(American Diagnostica Inc, Stamford, CT, USA). Each assay
contained a low level and a high level control. Inter-assay
coefficient of variation (CV) for the high level was 5% and for the
low level 21%. Normal values are ,400 ng/mL (95th percentile of
the normal distribution).
IL-6 was measured by Immunoassay Kit, Human IL-6,
Invitrogen Corporation, Camarillo, CA, USA. Since the kit did
not provide a control, culture medium from inflamed, IL-6
producing primary smooth muscle cells was used as an internal
control in each assay. The medium had been pre-tested in a
different laboratory for IL-6 content. Inter-assay CV for this high
level control was 24%. Normal reference range is: 720–12,000 pg/
mL.
sTM was measured by ELISA Eli-pair, Cell Sciences, Canton,
MA, USA. Normal plasma was used as an internal control (low
level) and the inter-assay CV was 38%. Normal values are
,44 ng/mL (95th percentile of the normal distribution).
sEPCR was measured by a previously employed, home-made
ELISA assay [14]. Briefly, microtiter plates (Nunc immuno plates
MaxiSorp 96 wells, Sigma) were coated with 50 mL of 7 mg/mL
JRK 1494, an anti-human EPCR mouse monoclonal antibody, in
15 mmol/L Na2CO3, 35 mmol/L NaHCO3, pH 9.6, at 4uC for
16 hours. The wells were washed five times with 20 mmol/L Tris-
HCl, 0.15 mol/L NaCl, 0.05% (v/v) Tween 20, pH 7.5 (washing
buffer), and were blocked with TBS-Casein (Bio-Rad Laborato-
ries, 300 mL each well) for 4 hours at 37uC. The wells were then
washed, 50 mL samples were added in duplicate wells, and the
plates were incubated for 1 h. The wells were aspirated, washed
five times with washing buffer, and 50 mL of 2,2 mg/mL
biotinilated JRK 1495 anti-human EPCR mouse monoclonal
antibody were added. The plates were incubated for 1 h, washed
five times, and 50 mL streptavidin–conjugated HRP diluted 1:3000
(Sigma) were added and incubated for one additional hour. The
wells were washed five times, and the substrate SIGMA FAST
OPD (o-phenylenediaminedihydrochloride, Sigma) was added.
The color development was stopped with 3 M H2SO4, and the
endpoint absorbance at 490 nm was read. Each plate contained
standards in duplicate wells from 62.5 to 1000 ng/mL purified
human soluble EPCR in washing buffer. The inter-assay CV was
7%.
Normal values are ,297 ng/mL (95th percentile of the normal
distribution).
Mouse monoclonal antibodies against human EPCR JRK1494
and JRK1495, as well as human soluble EPCR, were a kind gift of
C.T. Esmon (Cardiovascular Biology, Oklahoma Medical Re-
search Foundation, Oklahoma City, OK, U.S.A.).
All other tests were part of good clinical practice protocols and
were carried out at the central laboratory of the San Raffaele
Scientific Institute.
Statistical Analysis
Demographic, clinical and laboratory data were stored in an
electronic database. Results for continuous variables are reported
as median and range, for dichotomic variables as frequencies in
percent or absolute counts. Differences between groups for
dichotomic variables were evaluated by Fisher’s exact chi-square
test. Differences by time and by treatment group in continuous
variables were analysed first by analysis of variance for repeated
measures, and then by direct comparison. P values ,0.05 were
considered significant.
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Results
At baseline, 43 patients with not CCR5-tropic virus started
salvage antiretroviral therapy based on genotypic test: 4 (9%) with
enfuvirtide, 10 (24%) with protease inhibitors and 29 (67%) with
non nucleoside reverse transcriptase inhibitors; all patients
received raltegravir. Forty-five with CCR5-tropic virus started
therapy containing MVC: 8 (18%) at standard dosage (300 mg
twice daily); 9 (20%) in association with protease inhibitors
(150 mg twice daily); 28 (62%) in association with non nucleoside
reverse transcriptase inhibitors (600 mg twice daily).
Patients on ART and on ART with MVC (i.e. at start of MVC
therapy) differed for triglycerides and direct bilirubin levels only,
while age and all other laboratory variables were similar (Table 1).
Moreover, patients did not differ at baseline based on positivity for
HCV-antibodies, HBsAg or for the prevalence of hypertension.
Patients in stage C were 28/43 (65%) in ART and 24/45 (53%) in
ART with MVC (no significant difference between treatment
groups). There were proportionally more men than women in the
ART with MVC group compared to the ART only one (40 men, 5
women compared to 30 men, 13 women, x2 = 4.941, p,0.05).
Levels of some variables changed over time and differed in the
two groups. Figure 1 shows changes in metabolic variables and
CD4+ cell counts over time in patients on ART and in patients
who were administered MVC as well. Lipid profile was better in
the ART with MVC group, and improved or remained stable over
time. Especially HDL cholesterol increased sooner in the ART
with MVC group than in the ART only patients. As also shown in
the figure, CD4+ cell counts increased in both groups (p,0.001 at
48 weeks compared to baseline in both groups), but increments
were higher and occurred sooner in patients on MVC compared
to patients on traditional ART. Other CD4+ related variables
(CD4+ absolute count and percentage, CD4+/CD8+ ratio) varied
similarly to CD4+ cell counts, but did not show significant
differences between the two treatment groups at any time (not
shown). HIV-RNA decreased in both groups to undetectable levels
in the majority of patients by week 4 and remained low through
week 48 in both groups (Table 2).
An interim analysis of coagulation and inflammation markers in
the first 24 weeks showed no significant changes by time or by
treatment group in hsCRP, IL-6, D-dimer or sTM (not shown). In
general, median levels were within the normal range for CRP, IL-
6 and sTM in both groups, while median D-dimer levels were
increased above normal in both groups at all times. In contrast,
since sEPCR levels showed a trend to change by time and
treatment group, levels were measured beyond week 24 and are
reported in Table 3.
sEPCR increased in both treatment groups, and levels at week
36 and 48 were higher than at baseline (p,0.001 for both
treatment groups and both times). There were no differences
between the two groups at any time, however more patients had
levels above the reference range over the study time in the ART
only (n = 26) compared to the ART with MVC treatment group
(n= 18). If levels of soluble EPCR at week 48 above or below the
95th percentile of the normal range were considered and CD4+ cell
numbers were plotted separately for ART patients or ART with
MVC, two different graphs were obtained (Figure 2). In both
panels of Figure 2, CD4+ cells are observed to increase, as
mentioned previously, and increases are overall greater in ART
with MVC treated patients than in patients treated with ART
only, also as reported above. However, it is interesting to note that
in a group of ART with MVC treated patients who do not respond
adequately to therapy, i.e. whose median increase in CD4+ cells at
week 48 is less than 500 cells/mL, median levels of sEPCR at week
48 are high (2b). Also in ART treated patients levels of sEPCR are
higher in patients who respond less, though both curves are
persistently below the arbitrary threshold of 500 cells/mL
(Figure 2a). Finally, D-dimer levels are also shown in Figure 2
(dotted lines): differences are observed in D-dimer levels in patients
with high or low sEPCR levels at week 48. D-dimer levels changes
are apparently inversely related to CD4+ cell counts changes,
especially in MVC treated patients, though numbers were too
small for statistical analysis.
Discussion
In this study we observed that treatment experienced patients
with a CCR5-tropic HIV1 virus treated with MVC in addition to
ART showed a better lipid profile regardless of associated
treatment and a greater and more precocious increase in CD4+
cell counts over time compared to patients on ART alone, while
the decrease in viral load was comparable (by week 4 more than
50% and by week 48 more than 90% of patients had undetectable
levels of HIV mRNA in both groups). In naı¨ve patients, MVC
improved lipid profiles [15]. Observed CD4+ cell counts increases
are similar to those reported in previous larger studies [11,12].
Median CD4+ cell counts in the ART with MVC group were 500
cells/mL by week 36 and then leveled off.
Inflammation and coagulation markers were studied as well,
since both antiretroviral therapy and HIV infection are known
to induce an inflammatory response and coagulation activation
as a consequence of endothelial perturbation [6,7]. IL-6 and
hsPCR were low in both groups, indicating that patients
included in the study were apparently in a stable, non-inflamed
phase of the disease. D-dimer levels, a marker of fibrinolysis,
Table 1. Age and laboratory variables at baseline of patients
on ART (n = 43) or ART and MVC (n = 45).
Variable ART ART with MVC
Age (years) 47 (37–63) 46 (41–68)
CD4+ (/mL) 230 (4–653) 261 (19–911)
CD4p (%) 12.1 (0.4–30.3) 14.5 (2.4–37.2)
CD4/CD8 (ratio) 0.19 (0.01–0.89) 0.21 (0.04–0.9)
HIV-RNA (copies/mL) 15054 (99–711,230) 14513 (77–917,150)
HIV-DNA (copies/mL) 235 (9–7,834) 258 (9–5,858)
Total cholesterol (mg/dL) 179 (106–270) 176 (98–277)
HDL Cholesterol (mg/dL) 34 (21–170) 37 (17–77)
LDL Cholesterol (mg/dL) 98 (45–174) 103 (24–168)
Triglycerides (mg/dL) 214 (63–734)* 134 (57–497)*
Glucose (mg/dL) 84 (54–350) 85 (67–316)
Insulin 14 (5–77) 13 (2–227)
HOMA 3.14 (0.67–49.54) 2.35 (0.36–60.43)
AST 30 (9–108) 28 (17–123)
ALT 34 (9–175) 30 (11–135)
GGT 42 (6–251) 32 (11–444)
ALP 93 (38–426) 80 (17–519)
Total bilirubin 0.54 (0.21–2.37) 0.53 (0.21–0.98)
Direct bilirubin 0.21 (0.08–0.85)1 0.13 (0.07–0.34)1
Results are presented as median and range.
*p = 0.013 for direct comparison (Mann-Whitney).
1p= 0.003 for direct comparison (Mann-Whitney).
doi:10.1371/journal.pone.0037032.t001
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were not significantly different between the two treatment
groups and were only moderately increased compared to
normal. Soluble EPCR increased in both treatment groups
over time. Interestingly, the levels of sEPCR (above or below
the 95th percentile of the normal distribution) partially
discriminated between patients who achieved and patients who
did not achieve 500 CD4+ cells/mL by week 48. In general, the
slope of increase in CD4+ by high or low levels of sEPCR at
week 48 was significantly different. In patients who responded
to MVC an exponential increase in CD4+ cells was associated
with low levels of sEPCR at week 48 and low levels of D-dimer,
and the converse was true in patients who did not respond
adequately to MVC. The same trend were observed also in
patients on traditional ART, though less marked.
sEPCR is generated at the endothelial surface by cleavage of the
extracellular portion of the receptor. Cleavage occurs through a
metalloprotease [16], induced by endothelial activation by
thrombin, IL-1, TNF-a, or endotoxin, i.e. by coagulation and/
Figure 1. Changes in metabolic variables and CD4+ cell counts over time in patients on ART (solid line, squares) or ART with MVC
(broken line, circles). * denotes p,0.05 and ** p,0.01 for differences between the two patient groups at the time shown (Mann-Whitney test after
non parametric analysis of variance for repeated measures).
doi:10.1371/journal.pone.0037032.g001
Table 2. HIV-RNA copy levels by time and treatment group.
Time ART ART with MVC
HIV-RNA (Copies/mL)
N6 of patients
undetectable (%) HIV-RNA (Copies/mL)
N6 of patients undetectable
(%)
Baseline 15054 (99–711230) 0/43 (0) 14513 (77–917150) 0/45 (0)
Week 4 49 (49–8785) 27/42 (64) 49 (49–1435) 26/45 (58)
Week 12 49 (49–414678) 33/42 (79) 49 (49–51439) 34/45 (76)
Week 24 49 (49–173753) 35/42 (83) 49 (49–32935) 38/45 (84)
Week 36 49 (49–79798) 32/37 (86) 49 (49–314311) 35/42 (83)
Week 48 49 (49–623999) 33/35 (94) 49 (49–71702) 39/43 (91)
Data is presented as median and range. 49 copies is the lower limit of detection of the assay, and it was written in the database to indicate that the HIV-RNA was
undetectable.
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or inflammatory activation, though in vivo thrombin activation of
the endothelium seems to play the major role. sEPCR was shown
to be a very sensitive marker of endothelial dysfunction and
coagulation: for example, sEPCR levels were increased in sepsis
and lupus erythematosus, two conditions known to be associated
with inflammation and coagulation, more than soluble thrombo-
modulin, an established marker of endothelial damage that
belongs to the same anticoagulant pathway as EPCR [10]. In
the current study, the increase in sEPCR levels in some patients on
ART or ART with MVC treatment, even in the absence of an
increase in IL-6 or hsPCR, suggests a selective low level activation
of the endothelium by inflammation and coagulation. Moreover,
sEPCR is more sensitive to this inflammatory state than soluble
thrombomodulin which was found unchanged over time and
treatment group.
Three important suggestions can be derived from this study.
First, anti-HIV therapy seems to control inflammation and
coagulation, and is associated with an increase in CD4+ cells.
MVC increases faster and sooner the CD4+ cell count, but the
same relationship between CD4+ cell counts, sEPCR and D-dimer
can be observed also in ART treated patients, though it’s less
clear-cut. Second, a low-grade inflammatory and hypercoagulable
state is observed also in patients with stable long-lasting disease
and low levels of other, more traditional inflammatory and
coagulation markers. Third, some patients who do not respond to
therapy, either ART or MVC, by an increase in CD4+ cell counts,
independently of reduction in viral load, have a persistent or
increasing inflammation and coagulation activation. Fundenburg
and coworkers also reported that decreases in inflammatory and
immune markers in HIV+ patients were associated with an
increase in CD4+ cell counts.13 The authors also suggested that the
early, modest differential effect of MVC on several markers
compared to the comparator of the trial suggested an additional
direct effect of the drug on immune activation and inflammation.
Moreover, MVC was reported to decrease T cell activation and to
modulate the immune activation present in HIV patients, though
through which mechanism is not clear [17].
Elevated D-dimer was found to be strongly associated with
mortality and also to predict cardiovascular disease in HIV+
patients [18]. No studies of sEPCR were performed in HIV+
patients, but sEPCR levels were shown to be associated with a
hypercoagulable state and cardiovascular disease in diabetic
patients [19] and autoantibodies to EPCR were associated with
increased risk of myocardial infarction in women [20]. Coagula-
tion and inflammation are tightly linked and mutually enhancing,
thus strategies that control inflammation also are likely to control
Table 3. Median (range) levels of sEPCR.
Time ART ART with MVC
sEPCR (ng/mL)
Baseline 128 (71–576) 152 (81–400)
Week 4 131 (80–432) 144 (81–348)
Week 12 152 (84–504) 135 (73–432)
Week 24 138 (78–400) 127 (78–448)
Week 36 178 (108–496) 200 (132–456)
Week 48 186 (81–600) 189 (93–520)
doi:10.1371/journal.pone.0037032.t003
Figure 2. CD4+ cell counts (solid line) and D-dimer levels (broken line) in ART treated (panel a) or ART with MVC treated (panel b)
patients, by sEPCR levels at week 48 (high levels = red lines, low levels =blue lines). High or low sEPCR levels were defined as sEPCR $ or
,300 ng/mL (corresponding to the 95th percentile of the normal distribution). As specified in the text, D-dimers levels were measured in all patients
up to week 24, while sEPCR was measured in all patients up to weel 48.
doi:10.1371/journal.pone.0037032.g002
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coagulation activation. Furthermore, EPCR per se was shown to
possess multiple anti-inflammatory activities, so that shedding of
EPCR from the endothelium contributes to the loss of both
anticoagulant and anti-inflammatory potential, generating a
vicious cycle. Therapies, such as MVC, that inhibit viral entry
in the CD4+ cells and increase their numbers, have a potential to
control coagulation activation and inflammation in responsive
patients at least in the short term. In the setting of antiretroviral
naı¨ve patients, Maraviroc was not associated with elevations in
lipids and showed beneficial effects on lipid profiles of dyslipidemic
patients [21]. If confirmed in patients with higher inflammatory
levels and in longer follow-up time, such a therapeutic strategy
could potentially be effective also in preventing the cardiovascular
consequences of HIV infection associated with chronic inflamma-
tion.
Informed consent. All patients signed informed consent for
participation of Maraviroc Expanded Access Program.
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